{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T16:19:53Z","timestamp":1785255593017,"version":"3.55.0"},"reference-count":69,"publisher":"Deutscher Arzte-Verlag GmbH","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.3238\/arztebl.m2025.0238","type":"journal-article","created":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T10:39:24Z","timestamp":1776767964000},"source":"Crossref","is-referenced-by-count":2,"title":["Shorter versus longer antibiotic treatment in children with community-acquired pneumonia: A systematic review with meta-analyses"],"prefix":"10.3238","author":[{"given":"Alexander","family":"Benkendorff","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sibylle","family":"Puntscher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalena","family":"Flatscher-Th\u00f6ni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolai","family":"M\u00fchlberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"G\u00f6hner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Beck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anneke Clara","family":"Bergt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Krabbe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas L.","family":"Heise","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lea","family":"Gorenflo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siegbert","family":"Rieg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Hufnagel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Breuer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela M.","family":"Kunzler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uwe","family":"Siebert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rg J.","family":"Meerpohl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Schmucker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"11437","published-online":{"date-parts":[[2026,5,1]]},"reference":[{"key":"10.3238\/arztebl.m2025.0238_ref1","unstructured":"Bundesministerium f\u00fcr Gesundheit (ed.): DART 2030\u2013Deutsche Antibiotika-Resistenzstrategie. www.bundesgesundheitsministerium.de\/fileadmin\/Dateien\/3_Downloads\/A\/Antibiotika-Resistenz-Strategie\/DART_2030_bf.pdf (last accessed on 30 January 2025)."},{"key":"10.3238\/arztebl.m2025.0238_ref2","unstructured":"World Health Organization: Antimicrobial resistance. www.who.int\/news-room\/fact-sheets\/detail\/antimicrobial-resistance (last accessed on 30 January 2025)."},{"key":"10.3238\/arztebl.m2025.0238_ref3","doi-asserted-by":"crossref","unstructured":"Leach AJ, Shelby-James TM, Mayo M, et al.: A prospective study of the impact of community-based azithromycin treatment of trachoma on carriage and resistance of streptococcus pneumoniae. Clin Infect Dis 1997; 24: 356\u201362","DOI":"10.1093\/clinids\/24.3.356"},{"key":"10.3238\/arztebl.m2025.0238_ref4","doi-asserted-by":"crossref","unstructured":"Llewelyn MJ, Fitzpatrick JM, Darwin E, et al.: The antibiotic course has had its day. BMJ 2017; 358: j3418","DOI":"10.1136\/bmj.j3418"},{"key":"10.3238\/arztebl.m2025.0238_ref5","doi-asserted-by":"crossref","unstructured":"Spellberg B: The new antibiotic mantra\u2014\u201eshorter is better\u201c. JAMA Intern Med 2016; 176: 1254\u20135","DOI":"10.1001\/jamainternmed.2016.3646"},{"key":"10.3238\/arztebl.m2025.0238_ref6","doi-asserted-by":"crossref","unstructured":"Pichler PP, Jaccard IS, Weisz U, Weisz H: International comparison of health care carbon footprints. Environ Res Lett 2019; 14: 064004","DOI":"10.1088\/1748-9326\/ab19e1"},{"key":"10.3238\/arztebl.m2025.0238_ref7","doi-asserted-by":"crossref","unstructured":"Weisz U, Pichler PP, Jaccard IS, et al.: Carbon emission trends and sustainability options in Austrian health care. Resour Conserv Recycl 2020; 160: 104862","DOI":"10.1016\/j.resconrec.2020.104862"},{"key":"10.3238\/arztebl.m2025.0238_ref8","unstructured":"Richie C: Environmental sustainability and the carbon emissions of pharmaceuticals. J Med Ethics 2022; 48: 334\u20137."},{"key":"10.3238\/arztebl.m2025.0238_ref9","unstructured":"Statistisches Bundesamt (Destatis): Gesundheitsausgaben nach Leistungsarten. www.destatis.de\/DE\/Themen\/Gesellschaft-Umwelt\/Gesundheit\/Gesundheitsausgaben\/Tabellen\/leistungsarten.html (last accessed on 30 January 2025)."},{"key":"10.3238\/arztebl.m2025.0238_ref10","doi-asserted-by":"crossref","unstructured":"Morgenroth K, Opferkuch W: Abwehrsysteme der Lunge und Lungenentz\u00fcndung. Berlin, New York: De Gruyter 1991","DOI":"10.1515\/9783110875799"},{"key":"10.3238\/arztebl.m2025.0238_ref11","unstructured":"Statistisches Bundesamt (Destatis): Sterbef\u00e4lle, Sterbeziffern (ab\u00a01998). GBE\u2014Gesundheitsberichterstattung des Bundes. www.gbe-bund.de:443\/gbe\/isgbe.archiv?p_indnr=6&p_archiv_id=7234692&p_sprache=D&p_action=A (last accessed on 25 November 2025).\u00a0"},{"key":"10.3238\/arztebl.m2025.0238_ref12","doi-asserted-by":"crossref","unstructured":"Hansen G, Wetzke M, Baumann U, Schwerk N, Seidenberg J: Ambulant erworbene Pneumonie im Kindesalter. Monatsschr Kinderheilkd 2018; 166: 16\u201323","DOI":"10.1007\/s00112-017-0418-6"},{"key":"10.3238\/arztebl.m2025.0238_ref13","unstructured":"Sethi S: Ambulant erworbene Pneumonie. www.msdmanuals.com\/de-de\/profi\/lungenkrankheiten\/pneumonie\/ambulant-erworbene-pneumonie (last accessed on 30 January 2025)."},{"key":"10.3238\/arztebl.m2025.0238_ref14","unstructured":"Gesellschaft f\u00fcr P\u00e4diatrische Pneumologie e.V. (GPP), Deutsche Gesellschaft f\u00fcr P\u00e4diatrische Infektiologie e.V. (DGPI) (eds.): S2k-Leitlinie: Management der ambulant erworbenen Pneumonie bei Kindern und Jugendlichen (paediatric community-acquired pneumonia, pCAP). https:\/\/register.awmf.org\/assets\/guidelines\/048-013l_S2k_Management-ambulant-erworbene-Pneumonie-Kinder-Jugendlichen-paediatric-community-acquired_pneumonia-pCAP_2024-01_1.pdf (last accessed on 30 January 2025)."},{"key":"10.3238\/arztebl.m2025.0238_ref15","doi-asserted-by":"crossref","unstructured":"Pratt MTG, Abdalla T, Richmond PC, et al.: Prevalence of respiratory viruses in community-acquired pneumonia in children: A systematic review and meta-analysis. Lancet Child Adolesc Health 2022; 6: 555\u201370","DOI":"10.1016\/S2352-4642(22)00092-X"},{"key":"10.3238\/arztebl.m2025.0238_ref16","unstructured":"National Institute for Health and Care Excellence, Public Health England: Pneumonia: Diagnosis and management. NICE guideline NG250. www.nice.org.uk\/guidance\/ng250\/chapter\/Recommendations#antibiotic-treatment-for-community-acquired-pneumonia (last accessed on 29 November 2025)."},{"key":"10.3238\/arztebl.m2025.0238_ref17","doi-asserted-by":"crossref","unstructured":"Li Q, Zhou Q, Florez ID, et al.: Short-course vs long-course antibiotic therapy for children with nonsevere community-acquired pneumonia: A systematic review and meta-analysis. JAMA Pediatr 2022; 176: 1199\u2013207","DOI":"10.1001\/jamapediatrics.2022.4123"},{"key":"10.3238\/arztebl.m2025.0238_ref18","doi-asserted-by":"crossref","unstructured":"Haider BA, Saeed MA, Bhutta ZA: Short-course versus long-course antibiotic therapy for nonsevere community-acquired pneumonia in children aged 2 months to 59 months. Cochrane Database Syst Rev 2008: CD005976","DOI":"10.1002\/14651858.CD005976.pub2"},{"key":"10.3238\/arztebl.m2025.0238_ref19","doi-asserted-by":"crossref","unstructured":"Greenberg D, Givon-Lavi N, Sadaka Y, Ben-Shimol S, Bar-Ziv J, Dagan R: Short-course antibiotic treatment for community-acquired alveolar pneumonia in ambulatory children: A double-blind, randomized, placebo-controlled trial. Pediatr Infect Dis J 2014; 33: 136\u201342","DOI":"10.1097\/INF.0000000000000023"},{"key":"10.3238\/arztebl.m2025.0238_ref20","doi-asserted-by":"crossref","unstructured":"Bielicki JA, Stohr W, Barratt S, et al.: Effect of amoxicillin dose and treatment duration on the need for antibiotic re-treatment in children with community-acquired pneumonia: The CAP-IT randomized clinical trial. JAMA 2021; 326: 1713\u201324","DOI":"10.1001\/jama.2021.17843"},{"key":"10.3238\/arztebl.m2025.0238_ref21","doi-asserted-by":"crossref","unstructured":"Ginsburg AS, Mvalo T, Nkwopara E, et al.: Amoxicillin for 3 or 5 days for chest-indrawing pneumonia in malawian children. N Engl J Med 2020; 383: 13\u201323","DOI":"10.1056\/NEJMoa1912400"},{"key":"10.3238\/arztebl.m2025.0238_ref22","doi-asserted-by":"crossref","unstructured":"ISCAP Study Group, Agarwal G, Awasthi S, et al.: Three day versus five day treatment with amoxicillin for non-severe pneumonia in young children: A multicentre randomised controlled trial. BMJ 2004; 328: 791","DOI":"10.1136\/bmj.38049.490255.DE"},{"key":"10.3238\/arztebl.m2025.0238_ref23","doi-asserted-by":"crossref","unstructured":"Pakistan Multicentre Amoxycillin Short Course Therapy (MASCOT) pneumonia study group: Clinical efficacy of 3 days versus 5 days of oral amoxicillin for treatment of childhood pneumonia: A multicentre double-blind trial. Lancet 2002; 360: 835\u201341","DOI":"10.1016\/S0140-6736(02)09994-4"},{"key":"10.3238\/arztebl.m2025.0238_ref24","doi-asserted-by":"crossref","unstructured":"Pernica JM, Harman S, Kam AJ, et al.: Short-course antimicrobial therapy for pediatric community-acquired pneumonia: the SAFER randomized clinical trial. JAMA Pediatr 2021; 175: 475\u201382","DOI":"10.1001\/jamapediatrics.2020.6735"},{"key":"10.3238\/arztebl.m2025.0238_ref25","doi-asserted-by":"crossref","unstructured":"Williams DJ, Creech CB, Walter EB, et al.: Short- vs standard-course outpatient antibiotic therapy for community-acquired pneumonia in children: The SCOUT-CAP randomized clinical trial. JAMA Pediatr 2022; 176: 253\u201361","DOI":"10.1001\/jamapediatrics.2021.5547"},{"key":"10.3238\/arztebl.m2025.0238_ref26","doi-asserted-by":"crossref","unstructured":"Marques IR, Calvi IP, Cruz SA, et al.: Shorter versus longer duration of amoxicillin-based treatment for pediatric patients with community-acquired pneumonia: A systematic review and meta-analysis. Eur J Pediatr 2022; 181: 3795\u2013804","DOI":"10.1007\/s00431-022-04603-8"},{"key":"10.3238\/arztebl.m2025.0238_ref27","doi-asserted-by":"crossref","unstructured":"Verani JR, Groome MJ, Zar HJ, et al.: Risk factors for presumed bacterial pneumonia among HIV-uninfected children hospitalized in Soweto, South Africa. Pediatr Infect Dis J 2016; 35: 1169\u201374","DOI":"10.1097\/INF.0000000000001264"},{"key":"10.3238\/arztebl.m2025.0238_ref28","unstructured":"Rieck T, Feig M, Siedler A: Impfquoten von Kinderschutzimpfungen in Deutschland\u2014aktuelle Ergebnisse aus der RKI-Impfsurveillance. Epidemiologisches Bulletin 2022; 48: 3\u201325."},{"key":"10.3238\/arztebl.m2025.0238_ref29","unstructured":"World Health Organization: Pneumonia in children. www.who.int\/news-room\/fact-sheets\/detail\/pneumonia (last accessed on 25 October 2025)."},{"key":"10.3238\/arztebl.m2025.0238_ref30","doi-asserted-by":"crossref","unstructured":"Everson-Stewart S, Emerson SS: Bio-creep in non-inferiority clinical trials. Stat Med 2010; 29: 2769\u201380","DOI":"10.1002\/sim.4053"},{"key":"10.3238\/arztebl.m2025.0238_ref31","doi-asserted-by":"crossref","unstructured":"Jones B, Jarvis P, Lewis J, Ebbutt A: Trials to assess equivalence: The importance of rigorous methods. BMJ 1996; 313: 36\u20139","DOI":"10.1136\/bmj.313.7048.36"},{"key":"10.3238\/arztebl.m2025.0238_ref32","doi-asserted-by":"crossref","unstructured":"Suzumura EA, de Oliveira Ascef B, de Albuquerque Maia FH, et al.: Methodological guidelines and publications of benefit\u2013risk assessment for health technology assessment: A scoping review. BMJ Open 2024; 14: e086603","DOI":"10.1136\/bmjopen-2024-086603"},{"key":"10.3238\/arztebl.m2025.0238_ref33","doi-asserted-by":"crossref","unstructured":"Siebert U: When should decision-analytic modeling be used in the economic evaluation of health care? Eur J Health Econ 2003; 4: 143\u201350","DOI":"10.1007\/s10198-003-0205-2"},{"key":"10.3238\/arztebl.m2025.0238_ref34","doi-asserted-by":"crossref","unstructured":"Ginsburg AS, May S: Analysis of serious adverse events in a pediatric community-acquired pneumonia randomized clinical trial in Malawi. Sci Rep 2022; 12: 3538","DOI":"10.1038\/s41598-022-07582-w"},{"key":"10.3238\/arztebl.m2025.0238_ref35","doi-asserted-by":"crossref","unstructured":"Barratt S, Bielicki JA, Dunn D, et al.: Amoxicillin duration and dose for community-acquired pneumonia in children: The CAP-IT factorial non-inferiority RCT. Health Technol Assess 2021; 25: 1\u201372","DOI":"10.3310\/hta25600"},{"key":"10.3238\/arztebl.m2025.0238_ref36","doi-asserted-by":"crossref","unstructured":"Pettigrew MM, Kwon J, Gent JF, et al.: Comparison of the respiratory resistomes and microbiota in children receiving short versus standard course treatment for community-acquired pneumonia. mBio 2022; 13: e0019522.","DOI":"10.1128\/mbio.00195-22"},{"key":"10.3238\/arztebl.m2025.0238_ref37","doi-asserted-by":"crossref","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al.: The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021; 372: n71.","DOI":"10.1136\/bmj.n71"},{"key":"10.3238\/arztebl.m2025.0238_ref38","unstructured":"Institut f\u00fcr Qualit\u00e4t und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) (ed.): Antibiotikatherapie. F\u00fchrt eine verk\u00fcrzte Einnahmedauer zu vergleichbaren Behandlungsergebnissen? www.iqwig.de\/download\/t23-04_verkuerzte-antibiotikatherapie_vorlaeufiger-hta-bericht_v1-0.pdf (last accessed on 6 February 2025)."},{"key":"10.3238\/arztebl.m2025.0238_ref39","unstructured":"Institut f\u00fcr Qualit\u00e4t und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) (ed.): Allgemeine Methoden: Version 7.0. www.iqwig.de\/methoden\/allgemeine-methoden_version-7-0.pdf (last accessed on 30 January 2025)."},{"key":"10.3238\/arztebl.m2025.0238_ref40","unstructured":"European Medicines Agency (EMA), Committee for Medicinal Products for Human Use (CHMP): Addendum to the guideline on the evaluation of medicinal products indicated for treatment of bacterial infections. www.ema.europa.eu\/en\/documents\/scientific-guideline\/addendum-guideline-evaluation-medicinal-products-indicated-treatment-bacterial-infections_en.pdf (last accessed on 30 January 2025)."},{"key":"10.3238\/arztebl.m2025.0238_ref41","unstructured":"European Medicines Agency (EMA), Committee for Medicinal Products for Human Use (CHMP): Guideline on the evaluation of medicinal products indicated for treatment of bacterial infections. www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-evaluation-medicinal-products-indicated-treatment-bacterial-infections-revision-3_en.pdf (last accessed on 30 January 2025)."},{"key":"10.3238\/arztebl.m2025.0238_ref42","unstructured":"Institut f\u00fcr Qualit\u00e4t und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) (ed.): Antibiotikatherapie. F\u00fchrt eine verk\u00fcrzte Einnahmedauer zu vergleichbaren Behandlungsergebnissen? www.iqwig.de\/download\/t23-04_verkuerzte-antibiotikatherapie_themencheck-berichtsprotokoll_version1-0.pdf (last accessed on 6 February 2025)."},{"key":"10.3238\/arztebl.m2025.0238_ref43","unstructured":"Bundesinstitut f\u00fcr Arzneimittel und Medizinprodukte, GKV Spitzenverband: Festbetragsarzneimittel nach \u00a735 SGB V sortiert nach Arzneimittelname. www.bfarm.de\/SharedDocs\/Downloads\/DE\/Arzneimittel\/Zulassung\/amInformationen\/Festbetraege\/2024\/festbetraege-20240715.pdf?__blob=publicationFile (last accessed on 30 January 2025)."},{"key":"10.3238\/arztebl.m2025.0238_ref44","unstructured":"Kassen\u00e4rztliche Bundesvereinigung (KBV) (ed.): Einheitlicher Bewertungsma\u00dfstab (EBM); Stand: 1. Quartal 2024. https:\/\/www.kbv.de\/media\/sp\/EBM_Gesamt_-_Stand_1._Quartal_2024.pdf (last accessed on 30 January 2025)."},{"key":"10.3238\/arztebl.m2025.0238_ref45","unstructured":"Lauer-Fischer Portal: LAUER-TAXE Online 4.0. https:\/\/lto.cgmlauer.cgm.com\/LTO40.160101\/taxe (last accessed on 30 January 2025)."},{"key":"10.3238\/arztebl.m2025.0238_ref46","unstructured":"Schaaf N., Panorel I., Caputo A., et al.: Reducing emissions from antibiotic production. https:\/\/siwi.org\/wp-content\/uploads\/2020\/02\/reducing-emissions-from-antibiotic-production.pdf (last accessed on 30\u00a0January 2025)."},{"key":"10.3238\/arztebl.m2025.0238_ref47","doi-asserted-by":"crossref","unstructured":"Sonkar V, Venu V, Nishil B, Thatikonda S: Review on antibiotic pollution dynamics: Insights to occurrence, environmental behaviour, ecotoxicity, and management strategies. Environ Sci Pollut Res Int 2024; 31: 51164\u201396","DOI":"10.1007\/s11356-024-34567-1"},{"key":"10.3238\/arztebl.m2025.0238_ref48","doi-asserted-by":"crossref","unstructured":"Bound JP, Voulvoulis N: Household disposal of pharmaceuticals as a pathway for aquatic contamination in the United Kingdom. Environ Health Perspect 2005; 113: 1705\u201311.","DOI":"10.1289\/ehp.8315"},{"key":"10.3238\/arztebl.m2025.0238_ref49","doi-asserted-by":"crossref","unstructured":"Rizzo L, Manaia C, Merlin C, et al.: Urban wastewater treatment plants as hotspots for antibiotic resistant bacteria and genes spread into the environment: A review. Sci Total Environ 2013; 447: 345\u201360.","DOI":"10.1016\/j.scitotenv.2013.01.032"},{"key":"10.3238\/arztebl.m2025.0238_ref50","doi-asserted-by":"crossref","unstructured":"Parker E, Sawyer M, McCloskey A, Vasey N, Tse Y, Lim E: 729 EcoKidzMed: Measuring the carbon emissions of packaging, distribution and waste disposal of liquid and capsule amoxicillin. Arch Dis Child 2023; 108: A295-A6.","DOI":"10.1136\/archdischild-2023-rcpch.466"},{"key":"10.3238\/arztebl.m2025.0238_ref51","doi-asserted-by":"crossref","unstructured":"Littmann J, Buyx B: Antibiotikaresistenz: Ethische Aspekte einer dr\u00e4ngenden Herausforderung. Ethik in der Medizin 2015; 27: 301\u201314.","DOI":"10.1007\/s00481-014-0328-2"},{"key":"10.3238\/arztebl.m2025.0238_ref52","doi-asserted-by":"crossref","unstructured":"Davey P, Pagliari C, Hayes A: The patient\u2018s role in the spread and control of bacterial resistance to antibiotics. Clin Microbiol Infect 2002; 8: 43\u201368.","DOI":"10.1046\/j.1469-0691.8.s.2.6.x"},{"key":"10.3238\/arztebl.m2025.0238_ref53","doi-asserted-by":"crossref","unstructured":"Garau J: Impact of antibiotic restrictions: The ethical perspective. Clin Microbiol Infect 2006; 12: 16\u201324.","DOI":"10.1111\/j.1469-0691.2006.01527.x"},{"key":"10.3238\/arztebl.m2025.0238_ref54","doi-asserted-by":"crossref","unstructured":"Pina JC, Alves LS, Arroyo LH, et al.: Using geo-spatial analysis for assessing the risk of hospital admissions due to community-acquired pneumonia in under-5 children and its association with socially vulnerable areas (Brazil). BMC Pediatrics 2020; 20: 502.","DOI":"10.1186\/s12887-020-02398-x"},{"key":"10.3238\/arztebl.m2025.0238_ref55","doi-asserted-by":"crossref","unstructured":"Antonelli F, De Brasi D, Siani P: Appropriateness of hospitalization for CAP-affected pediatric patients: Report from a southern Italy general hospital. Ital J Pediatr 2009; 35: 26.","DOI":"10.1186\/1824-7288-35-26"},{"key":"10.3238\/arztebl.m2025.0238_ref56","doi-asserted-by":"crossref","unstructured":"Calvillo\u2013King L, Arnold D, Eubank KJ, et al.: Impact of social factors on risk of readmission or mortality in pneumonia and heart failure: Systematic review. J Gen Intern Med 2013; 28: 269\u201382.","DOI":"10.1007\/s11606-012-2235-x"},{"key":"10.3238\/arztebl.m2025.0238_ref57","doi-asserted-by":"crossref","unstructured":"Lawrence H, McKeever TM, Lim WS: Impact of social deprivation on clinical outcomes of adults hospitalised with community-acquired pneumonia in England: A retrospective cohort study. BMJ Open Respir Res 2022; 9: e001318.","DOI":"10.1136\/bmjresp-2022-001318"},{"key":"10.3238\/arztebl.m2025.0238_ref58","doi-asserted-by":"crossref","unstructured":"Kardas P, Lewek P, Matyjaszczyk M: Determinants of patient adherence: A review of systematic reviews. Front Pharmacol 2013; 4: 91.","DOI":"10.3389\/fphar.2013.00091"},{"key":"10.3238\/arztebl.m2025.0238_ref59","doi-asserted-by":"crossref","unstructured":"Sedrak A, Anpalahan M, Luetsch K: Enablers and barriers to the use of antibiotic guidelines in the assessment and treatment of community-acquired pneumonia\u2014a qualitative study of clinicians\u2019 perspectives. Int J Clin Pract 2017; 71: e12959.","DOI":"10.1111\/ijcp.12959"},{"key":"10.3238\/arztebl.m2025.0238_ref60","doi-asserted-by":"crossref","unstructured":"Dominguez F, Gaffin N, Davar K, et al.: How to change the course: Practical aspects of implementing shorter is better. Clin Microbiol Infect 2023; 29: 1402\u20136.","DOI":"10.1016\/j.cmi.2022.07.025"},{"key":"10.3238\/arztebl.m2025.0238_ref61","doi-asserted-by":"crossref","unstructured":"Ayorinde A, Ghosh I, Shaikh J, et al.: Improving healthcare professionals\u2019 interactions with patients to tackle antimicrobial resistance: A systematic review of interventions, barriers, and facilitators. Front Public Health 2024; 12: 1359790.","DOI":"10.3389\/fpubh.2024.1359790"},{"key":"10.3238\/arztebl.m2025.0238_ref62","doi-asserted-by":"crossref","unstructured":"Livorsi DJ, Drainoni M-L, Reisinger HS, et al.: Leveraging implementation science to advance antibiotic stewardship practice and research. Infect Control Hosp Epidemiol 2022; 43: 139\u201346.","DOI":"10.1017\/ice.2021.480"},{"key":"10.3238\/arztebl.m2025.0238_ref63","unstructured":"GRADEpro (Evidence Prime Inc.): GRADEpro GDT: GRADEpro guideline development tool [Software]. www.gradepro.org\/ (last accessed on 30 January 2025)."},{"key":"10.3238\/arztebl.m2025.0238_ref64","doi-asserted-by":"crossref","unstructured":"McGowan J, Sampson M, Salzwedel DM, Cogo E, Foerster V, Lefebvre C: PRESS peer review of electronic search strategies: 2015 guideline statement. J Clin Epidemiol 2016; 75: 40\u20136.","DOI":"10.1016\/j.jclinepi.2016.01.021"},{"key":"10.3238\/arztebl.m2025.0238_ref65","doi-asserted-by":"crossref","unstructured":"Marckmann G, Schmidt H, Sofaer N, Strech D: Putting public health ethics into practice: A systematic framework. Front Public Health 2015; 3: 23.","DOI":"10.3389\/fpubh.2015.00023"},{"key":"10.3238\/arztebl.m2025.0238_ref66","unstructured":"Lysdahl, KB, Mozygemba, K, Burns, J, Chilcott, JB, Broenneke, JB, Hofmann, B (eds.): Guidance for assessing effectiveness, economic aspects, ethical aspects, socio-cultural aspects and legal aspects in complex technologies [Online]. Available from: \/www.integrate-hta.eu\/downloads\/ (last accessed on 30 January 2025)."},{"key":"10.3238\/arztebl.m2025.0238_ref67","unstructured":"Perleth M, Gibis B, Velasco Garrido M, Zentner A: Organisationsstrukturen und Qualit\u00e4t. In: Perleth M, Busse R, Gerhardus A, Gibis B, Luehmann D, Zentner A (eds.): Health Technology Assessment; Konzepte, Methoden, Praxis f\u00fcr Wissenschaft und Entscheidungsfindung (2nd edition, revised and extended). Berlin: Medizinisch Wissenschaftliche Verlagsgesellschaft 2014; 265\u201379."},{"key":"10.3238\/arztebl.m2025.0238_ref68","unstructured":"Lefebvre C, Glanville J, Briscoe S, et al.: Technical Supplement to Chapter 4: Searching for and selecting studies. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (eds.). Cochrane Handbook for Systematic Reviews of Interventions version 6.5. Cochrane, 2024. Available from www.training.cochrane.org\/handbook (last accessed on 30 January 2025)."},{"key":"10.3238\/arztebl.m2025.0238_ref69","unstructured":"Glanville J, Lefebvre C, Manson P, Robinson S, Brbre I and Woods L (eds.). York (UK): The InterTASC Information Specialists\u2018 Sub-Group: ISSG Search Filter Resource. Available from https:\/\/sites.google.com\/a\/york.ac.uk\/issg-search-filters-resource\/home (last accessed on 30 January 2025)."}],"container-title":["Deutsches \u00c4rzteblatt international"],"original-title":[],"link":[{"URL":"https:\/\/www.aerzteblatt.de\/10.3238\/arztebl.m2025.0238","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T10:39:57Z","timestamp":1776767997000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.aerzteblatt.de\/10.3238\/arztebl.m2025.0238"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,1]]},"references-count":69,"URL":"https:\/\/doi.org\/10.3238\/arztebl.m2025.0238","relation":{},"ISSN":["1866-0452"],"issn-type":[{"value":"1866-0452","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,1]]}}}